Augmented O-GlcNAcylation attenuates intermittent hypoxia-induced cardiac remodeling through the suppression of NFAT and NF-κB activities in mice.


Journal

Hypertension research : official journal of the Japanese Society of Hypertension
ISSN: 1348-4214
Titre abrégé: Hypertens Res
Pays: England
ID NLM: 9307690

Informations de publication

Date de publication:
12 2019
Historique:
received: 01 03 2019
accepted: 03 07 2019
revised: 04 06 2019
pubmed: 15 8 2019
medline: 5 11 2020
entrez: 15 8 2019
Statut: ppublish

Résumé

Type 2 diabetes mellitus (T

Identifiants

pubmed: 31409917
doi: 10.1038/s41440-019-0311-x
pii: 10.1038/s41440-019-0311-x
doi:

Substances chimiques

NF-kappa B 0
NFATC Transcription Factors 0
N-Acetylglucosaminyltransferases EC 2.4.1.-
UDP-N-acetylglucosamine-peptide beta-N-acetylglucosaminyltransferase EC 2.4.1.-
Glycogen Synthase Kinase 3 beta EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1858-1871

Commentaires et corrections

Type : CommentIn

Références

Torres CR, Hart GW. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem. 1984;2595:3308–17.
Hart GW, Housley MP, Slawson C. Cycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 2007;4467139:1017–22.
doi: 10.1038/nature05815
Hart GW, Greis KD, Dong LY, Blomberg MA, Chou TY, Jiang MS et al. O-linked N-acetylglucosamine: the “yin-yang” of Ser/Thr phosphorylation? Nuclear and cytoplasmic glycosylation. Adv Exp Med Biol. 1995;376:115–23.
doi: 10.1007/978-1-4615-1885-3_10
Kamemura K, Hart GW. Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: a new paradigm for metabolic control of signal transduction and transcription. Prog Nucleic Acid Res Mol Biol. 2003;73:107–36.
doi: 10.1016/S0079-6603(03)01004-3
Lanfranchi PA, Somers VK, Braghiroli A, Corra U, Eleuteri E, Giannuzzi P. Central sleep apnea in left ventricular dysfunction: prevalence and implications for arrhythmic risk. Circulation. 2003;1075:727–32.
doi: 10.1161/01.CIR.0000049641.11675.EE
Jensen RV, Johnsen J, Kristiansen SB, Zachara NE, Bøtker HE. Ischemic preconditioning increases myocardial O-GlcNAc glycosylation. Scand Cardiovasc J. 2013;473:168–74.
doi: 10.3109/14017431.2012.756984
Champattanachai V, Marchase RB, Chatham JC. Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein O-GlcNAc and increased mitochondrial Bcl-2. Am J Physiol Cell Physiol. 2008;2946:C1509–20.
doi: 10.1152/ajpcell.00456.2007
Genovese A, Chiariello M, Cacciapuoti AA, De Alfieri W, Latte S, Condorelli M. Inhibition of hypoxia-induced cardiac hypertrophy by verapamil in rats. Basic Res Cardiol. 1980;756:757–63.
doi: 10.1007/BF01910453
Liu J, Marchase RB, Chatham JC. Increased O-GlcNAc levels during reperfusion lead to improved functional recovery and reduced calpain proteolysis. Am J Physiol Heart Circ Physiol. 2007;2933:H1391–9.
doi: 10.1152/ajpheart.00285.2007
Liu J, Pang Y, Chang T, Bounelis P, Chatham JC, Marchase RB. Increased hexosamine biosynthesis and protein O-GlcNAc levels associated with myocardial protection against calcium paradox and ischemia. J Mol Cell Cardiol. 2006;402:303–12.
doi: 10.1016/j.yjmcc.2005.11.003
Lunde IG, Aronsen JM, Kvaløy H, Qvigstad E, Sjaastad I, Tønnessen T et al. Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure. Physiol Genomics. 2012;442:162–72.
doi: 10.1152/physiolgenomics.00016.2011
Ngoh GA, Facundo HT, Zafir A, Jones SP. O-GlcNAc signaling in the cardiovascular system. Circ Res. 2010;1072:171–85.
doi: 10.1161/CIRCRESAHA.110.224675
Wilkins BJ, Molkentin JD. Calcium–calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun. 2004;3224:1178–91.
doi: 10.1016/j.bbrc.2004.07.121
Moriwaki K, Asahi M. Augmented TME O-GlcNAcylation Promotes Tumor Proliferation through the Inhibition of p38 MAPK. Mol Cancer Res. 2017;159:1287–98.
doi: 10.1158/1541-7786.MCR-16-0499
Nishioka S, Yoshioka T, Nomura A, Kato R, Miyamura M, Okada Y et al. Celiprolol reduces oxidative stress and attenuates left ventricular remodeling induced by hypoxic stress in mice. Hypertens Res. 2013;36:934.
doi: 10.1038/hr.2013.60
Kato R, Nomura A, Sakamoto A, Yasuda Y, Amatani K, Nagai S et al. Hydrogen gas attenuates embryonic gene expression and prevents left ventricular remodeling induced by intermittent hypoxia in cardiomyopathic hamsters. Am J Physiol Heart Circ Physiol. 2014;30711:H1626–H1633.
doi: 10.1152/ajpheart.00228.2014
Yamashita C, Hayashi T, Mori T, Tazawa N, Kwak C-J, Nakano D et al. Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein e–knockout mice. Hypertens Res. 2007;30:1219.
doi: 10.1291/hypres.30.1219
Anversa P, Kajstura J, Leri A, Bolli R. Life and death of cardiac stem cells: a paradigm sahift in cardiac biology. Circulation. 2006;11311:1451–63.
doi: 10.1161/CIRCULATIONAHA.105.595181
Kawamura N, Kubota T, Kawano S, Monden Y, Feldman AM, Tsutsui H et al. Blockade of NF-kappaB improves cardiac function and survival without affecting inflammation in TNF-alpha-induced cardiomyopathy. Cardiovasc Res. 2005;663:520–9.
doi: 10.1016/j.cardiores.2005.02.007
Molkentin JD. Calcineurin–NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res. 2004;633:467–75.
doi: 10.1016/j.cardiores.2004.01.021
Pantaleon M, Tan HY, Kafer GR, Kaye PL. Toxic effects of hyperglycemia are mediated by the hexosamine signaling pathway and O-linked glycosylation in early mouse embryos. Biol Rep. 2010;824:751–8.
doi: 10.1095/biolreprod.109.076661
Martinez Ceron E, Casitas Mateos R, Garcia-Rio F. Sleep apnea-hypopnea syndrome and type 2 diabetes. A reciprocal relationship? Arch Bronconeumol. 2015;513:128–39.
Liang Q, Bueno OF, Wilkins BJ, Kuan CY, Xia Y, Molkentin JD. c‐Jun N‐terminal kinases (JNK) antagonize cardiac growth through cross‐talk with calcineurin–NFAT signaling. EMBO J. 2003;2219:5079.
doi: 10.1093/emboj/cdg474
Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation. 2002;1054:509–15.
doi: 10.1161/hc0402.102863
Hayashi T, Yoshioka T, Hasegawa K, Miyamura M, Mori T, Ukimura A et al. Inhalation of hydrogen gas attenuates left ventricular remodeling induced by intermittent hypoxia in mice. Am J Physiol Heart Circ Physiol. 2011;3013:H1062–9.
doi: 10.1152/ajpheart.00150.2011
Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 1991;2668:4706–12.
Gurel Z, Sieg KM, Shallow KD, Sorenson CM, Sheibani N. Retinal O-linked N-acetylglucosamine protein modifications: implications for postnatal retinal vascularization and the pathogenesis of diabetic retinopathy. Mol Vis. 2013;19:1047–59.
pubmed: 23734074 pmcid: 3668662
Park MJ, Kim DI, Lim SK, Choi JH, Han HJ, Yoon KC et al. High glucose-induced O-GlcNAcylated carbohydrate response element-binding protein (ChREBP) mediates mesangial cell lipogenesis and fibrosis: the possible role in the development of diabetic nephropathy. J Biol Chem. 2014;28919:13519–30.
doi: 10.1074/jbc.M113.530139
Yokoe S, Asahi M, Takeda T, Otsu K, Taniguchi N, Miyoshi E et al. Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy. Glycobiology. 2010;2010:1217–26.
doi: 10.1093/glycob/cwq071
Shi J, Wu S, Dai CL, Li Y, Grundke-Iqbal I, Iqbal K et al. Diverse regulation of AKT and GSK-3beta by O-GlcNAcylation in various types of cells. FEBS Lett. 2012;58616:2443–50.
doi: 10.1016/j.febslet.2012.05.063

Auteurs

Takatoshi Nakagawa (T)

Department of Pharmacology, Osaka Medical College, Osaka, Japan.

Yuichi Furukawa (Y)

Department of Pharmacology, Osaka Medical College, Osaka, Japan.
Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Osaka, Japan.

Tetsuya Hayashi (T)

Department of Pharmacology, Osaka Medical College, Osaka, Japan.
Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Osaka, Japan.

Atsuo Nomura (A)

Department of Pharmacology, Osaka Medical College, Osaka, Japan.
Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Osaka, Japan.

Shunichi Yokoe (S)

Department of Pharmacology, Osaka Medical College, Osaka, Japan.

Kazumasa Moriwaki (K)

Department of Pharmacology, Osaka Medical College, Osaka, Japan.

Ryuji Kato (R)

Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Osaka, Japan.

Yoshio Ijiri (Y)

Department of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences, Osaka, Japan.

Takehiro Yamaguchi (T)

Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.
Department of Pharmacology, Osaka City University Graduate School of Medicine, Osaka, Japan.

Yasukatsu Izumi (Y)

Department of Pharmacology, Osaka City University Graduate School of Medicine, Osaka, Japan.

Minoru Yoshiyama (M)

Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.

Michio Asahi (M)

Department of Pharmacology, Osaka Medical College, Osaka, Japan. masahi@osaka-med.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH